Grant Pickering - Dec 9, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol: PCVX
Transactions as of: Dec 9, 2024
Transactions value $: -$218,253
Form type: 4
Date filed: 12/10/2024, 04:10 PM
Previous filing: Dec 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCVX	Common Stock	Sale	-$88.5K	-961	-0.7%	$92.06	136K	Dec 9, 2024	By Children's Trust	F1, F2, F3
transaction	PCVX	Common Stock	Sale	-$20.7K	-222	-0.16%	$93.10	136K	Dec 9, 2024	By Children's Trust	F1, F3, F4
transaction	PCVX	Common Stock	Sale	-$94.7K	-1.03K	-0.75%	$92.03	136K	Dec 9, 2024	By Children's Trust	F1, F5, F6
transaction	PCVX	Common Stock	Sale	-$14.4K	-154	-0.11%	$93.60	136K	Dec 9, 2024	By Children's Trust	F1, F6, F7
holding	PCVX	Common Stock						450K	Dec 9, 2024	Direct

Showing 1 to 5 of 5 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024.
F2	The price reported is a weighted-average price. The shares were sold at prices ranging from $91.615 to $92.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3	Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
F4	The price reported is a weighted-average price. The shares were sold at prices ranging from $92.80 to $93.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	The price reported is a weighted-average price. The shares were sold at prices ranging from $91.715 to $92.63. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6	Shares are held directly by a trust for the benefit of the Reporting Person's son.
F7	The price reported is a weighted-average price. The shares were sold at prices ranging from $93.355 to $93.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.